CAR-T治疗失败的“拦路虎”:anti-CAR免疫反应 原文链接 CAR-T免疫细胞治疗,在国内外都取得了巨大突破。国内2021年6月22日复星凯特靶向CD19的CAR-T细胞治疗产品益基利仑赛注射液(又称阿基仑赛,代号:FKC876)已正式获批上市,9月3日药明巨诺靶向CD19的CAR-T产品瑞基奥仑赛注射液(relma-cel,商品名:倍诺达)也正式...
FMC63是一种靶向人CD19的鼠单克隆抗体。到目前为止,大多数报道的CART19试验项目均是以FMC63抗体序列为基础构建的CAR-T,包括FDA批准上市的两种Anti-CD19 CAR-T细胞药物Kymriah和Yescarta。根据2018年中检院颁布的《CAR-T细胞治疗产品质量控制检测研究及非临床研究考虑要点》,CAR转染阳性率的检测应采用流式细胞法,推荐...
Despite recent advances in anti-CD19 therapy, no clinical evidence exists to direct the sequencing of CAR T cell therapy following relapse after prior anti-CD19 therapy. We present the first published case of TAFA/LEN treatment followed by CAR T therapy with sustained remission. Disease ...
will explore the most important studies and clinical trials on CNSL, focusing on recent advancements in anti-CD19 CAR T-cell therapy. This comprehensive analysis will offer insights into the successes and challenges of treating CNSL effectively. Author information Authors and Affiliations Clinical Hemato...
肿瘤医院淋巴血液肿瘤科的岑洪主任仔细研究了患者的病情,决定给患者进行PD-1敲减的anti-CD19 CAR-T细胞治疗。医生采集患者的外周血,武汉张同存教授团队进行CAR-T细胞培养,经过10多天的培养,CAR-T细胞达到了治疗所需的剂量。徐女士说,看着细胞输入体内,我的心情是很忐忑的,我知道这是最后的希望,万一没效...我不...
First, we assessed the clinical response of CNSL to CAR-T therapy in these patients. All patients with CNSL achieved CR approximately one to two weeks post CAR-T infusion (Fig.1a–c), accompanied by BM remission with MRD negative in patient 2 and patient 3 (Fig.1d). One month after ...
Anti-CD19 chimeric antigen receptor (CAR) T cell therapies can cause severe cytokine-release syndrome (CRS) and neurotoxicity, impeding their therapeutic application. Here we generated a new anti-CD19 CAR molecule (CD19-BBz(86)) derived from the CD19-BBz prototype bearing co-stimulatory 4-1...
另外值得关注的是,LOTIS-2研究中纳入了预后较差的R/R HGBCL和接受过anti-CD19 CAR-T细胞治疗后复发的患者,这些人群常常被新药临床试验排除而只能接受挽救治疗,但LOTIS-2研究的两篇事后分析说明了Lonca单药对于这两类人群的治疗潜力,ORR分别为45.5%和46.2%,和入组的整体人群基本无差异。这进一步证明PBD和其它化疗...
We aimed to develop an optimized process for producing Hu19-CD828Z-expressing T cells (Hu19-CAR T) from PBMC of CLL patients. We determined that supplementing Hu19-CAR-T cultures with interleukin (IL)-7 + IL-15 had advantages over using IL-2, including greater accumulation of Hu19-CAR...
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is effective in patients with advanced B-cell acute lymphoblastic leukemia (B-ALL). However, efficacy data is sparse in subgroups of patients with high-risk features such as BCR-ABL+, TP53 mutation, extramedullary disease (including centra...